Kilambi News
Wednesday, November 18, 2026

Archive

Every story, newest first.

Tuesday, November 17, 2026

Rates

Musalem says several rate hikes likely needed by spring

St. Louis Fed President Alberto Musalem said the Federal Reserve will likely need several interest rate increases before the spring of 2027, arguing the policy rate, at 3.75% to 4%, may be as much as a percentage point too low to return inflation to target.

Rates

JPMorgan names de Best to succeed Barnum as finance chief

JPMorgan Chase has named Bregje de Best, finance chief of its Commercial and Investment Bank, to succeed Jeremy Barnum as chief financial officer after the bank's first-quarter 2027 reporting, with Barnum becoming a vice chairman.

Technology

Disney fourth-quarter profit jumps as revenue rises 16 percent

Walt Disney reported fiscal fourth-quarter revenue of $25.9 billion, up 16 percent from a year earlier, with diluted earnings per share more than doubling to $1.51 from $0.73.

Politics

Politics also notable: Quad leaders meet in Manila, Serbia students enter parliament, WTO warning

The Quad leaders met in Manila, with President Trump announcing more than $85 million for Indo-Pacific AI ecosystems, new critical minerals agreements and a first Quad Business Leaders Forum in 2027, while Serbia's student movement candidates prepared to be sworn in as MPs and the WTO reported a surge in new trade-restrictive measures.

Mining

Mining also notable: Perenti wins Geita renewal, Ottawa backs Mactung tungsten

Perenti's AUMS won a five-year, A$1 billion underground contract renewal at AngloGold Ashanti's Geita gold mine, and Canada conditionally approved up to C$14 million for Fireweed Metals' Mactung tungsten project.

Life Sciences

Life sciences also notable: Capsida trial follow-up, Helus depression data

STAT reported follow-up progress after a patient death in Capsida's gene therapy trial, a psychedelic drug from Helus improved depression in a study while raising safety questions, and Flagship Pioneering launched a UK lab venture with 100 million pounds.

Life Sciences

Johnson & Johnson buys Ollin Biosciences for up to $3.3 billion

Johnson & Johnson will acquire eye drug developer Ollin Biosciences for $2.2 billion upfront plus $1.1 billion in milestones, a deal worth up to $3.3 billion.

Infrastructure

Infra-deals also notable: EU recovery payments, UK merger inquiry, Pentagon bill

The European Commission partially greenlit recovery fund payments of 2.67 billion euros for Romania and 548 million euros for Slovakia, the UK competition authority opened a merger inquiry into Mari and ATG Entertainment, and Senate Republicans unveiled a nearly $1.1 trillion defense appropriations bill.

Commodities

Commodities also notable: KOGAS pays up, US port imports top one million TEU

A Seoul appeals court ordered KOGAS to pay about $200 million over defective LNG carrier tanks, and United States West Coast import containers passed one million TEU in October for only the second time.

Life Sciences

CG Oncology drug cuts bladder cancer recurrence risk 68 percent

CG Oncology's cretostimogene cut the risk of bladder cancer recurrence by 68 percent versus surveillance after surgery in a Phase 3 trial, and its shares climbed 12 percent.